[go: up one dir, main page]

NO20055150L - Benzotiazolderivater som adenosin-reseptorligander - Google Patents

Benzotiazolderivater som adenosin-reseptorligander

Info

Publication number
NO20055150L
NO20055150L NO20055150A NO20055150A NO20055150L NO 20055150 L NO20055150 L NO 20055150L NO 20055150 A NO20055150 A NO 20055150A NO 20055150 A NO20055150 A NO 20055150A NO 20055150 L NO20055150 L NO 20055150L
Authority
NO
Norway
Prior art keywords
optionally substituted
lower alkyl
aza
halogen
alkyl
Prior art date
Application number
NO20055150A
Other languages
English (en)
Inventor
Roland Jakob-Roetne
Claus Riemer
Alexander Flohr
Roger David Norcross
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20055150L publication Critical patent/NO20055150L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Oppfinnelsen angår forbindelser med den generelle formel hvor R1 er 1,4-dioksepanyl eller tetrahydropyran-4-yl; R2 er -N(R)-(CH2)n-5-eller 6-leddet ikke-aromatisk heterocyklisk gruppe, eventuelt substituert med én eller flere substituenter, valgt fra gruppen bestående av lavere alkyl eller-NR2, eller er -(CH2)n-5-eller 6 leddet ikke-aromatisk heterocyklisk gruppe, eventuelt substituert med -(CH2)n-OH, lavere alkyl, lavere alkoksy, eller er -CH2)n-5-eller 6-leddet aromatisk heterocyklisk gruppe, eventuelt substituert med lavere alkyl, lavere alkoksy, halogen, halogen-lavere alkyl, -CH2N(R)(CH2)2OCH3, -N(R)(CH2)2OCH3, -CH2-morfolinyl eller-CH2-pyrrolidinyl, eller er (CH2)n-cykloalkyl, eventuelt substituert med hydroksy eller er -N(R)-cykloalkyl, eventuelt substituert med hydroksy eller lavere alkyl, eller erfenyl, eventuelt substituert med lavere alkoksy, halogen, halogen-lavere-alkyl, lavere alkyl, -CH2-pyrrolidin-1-yl, -CH2-morfolinyl, -CH2N(R)(CH2)2OCH3 eller-CH2- N(R)C(O)-lavere alkyl, eller er 1,4-dioksa-8-aza-spiro[4.5]dekan, eller er2-oksa-5-aza-bicyklo[2.2.1]heptan, eller er 1-oksa-8-aza-spiro[4.5]dekan, eller er-N(R)-7-oksa-bicyklo[2.2.1]hept-2-yl eller er 2-aza-bicyklo[2.2.2]dekan; R er hydrogen eller lavere alkyl; n er 0 eller 1; og farmasøytisk akseptable syreaddisjonssalter derav for behandling av sykdommer, som angår A2A-reseptoren.
NO20055150A 2003-05-19 2005-11-03 Benzotiazolderivater som adenosin-reseptorligander NO20055150L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03011039 2003-05-19
PCT/EP2004/005178 WO2005000842A1 (en) 2003-05-19 2004-05-14 Benzothiazole derivatives as adenosine receptor ligands

Publications (1)

Publication Number Publication Date
NO20055150L true NO20055150L (no) 2005-11-04

Family

ID=33442729

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055150A NO20055150L (no) 2003-05-19 2005-11-03 Benzotiazolderivater som adenosin-reseptorligander

Country Status (27)

Country Link
US (1) US7371748B2 (no)
EP (1) EP1636223B1 (no)
JP (1) JP4444290B2 (no)
KR (1) KR100859886B1 (no)
CN (1) CN100528871C (no)
AR (1) AR044362A1 (no)
AT (1) ATE389652T1 (no)
AU (1) AU2004251814B2 (no)
BR (1) BRPI0410440A (no)
CA (1) CA2524366C (no)
CL (1) CL2004001067A1 (no)
CO (1) CO5630031A2 (no)
DE (1) DE602004012555T2 (no)
DK (1) DK1636223T3 (no)
ES (1) ES2301991T3 (no)
HR (1) HRP20080207T3 (no)
IL (1) IL171686A (no)
MX (1) MXPA05012360A (no)
NO (1) NO20055150L (no)
NZ (1) NZ543074A (no)
PL (1) PL1636223T3 (no)
PT (1) PT1636223E (no)
RU (1) RU2351597C2 (no)
SI (1) SI1636223T1 (no)
TW (1) TW200505882A (no)
WO (1) WO2005000842A1 (no)
ZA (1) ZA200509294B (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008052930A2 (en) * 2006-11-03 2008-05-08 F. Hoffmann-La Roche Ag Preparation of 4-alk0xy-7- (tetrahydropyran-4-yl) benzothiazol-2-amine derivatives
EP3661941B1 (en) * 2017-08-01 2022-12-14 Merck Patent GmbH Thiazolopyridine derivatives as adenosine receptor antagonists
CN110997662B (zh) 2017-08-21 2023-10-31 默克专利股份公司 作为腺苷受体拮抗剂的苯并咪唑衍生物
US11192899B2 (en) 2017-08-21 2021-12-07 Merck Patent Gmbh Quinoxaline derivatives as adenosine receptor antagonists
WO2019141096A1 (zh) * 2018-01-19 2019-07-25 四川科伦博泰生物医药股份有限公司 取代脲类化合物及其制备方法和用途
BR112021007435A2 (pt) 2018-10-25 2021-08-03 Merck Patent Gmbh derivados de 5-azaindazol como antagonistas de receptor de adenosina
WO2020083856A1 (en) 2018-10-25 2020-04-30 Merck Patent Gmbh 5-azaindazole derivatives as adenosine receptor antagonists
AR117844A1 (es) * 2019-01-22 2021-09-01 Merck Patent Gmbh Derivados de tiazolopiridina como antagonistas del receptor de adenosina

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI91859C (fi) * 1987-06-17 1994-08-25 Eisai Co Ltd Analogiamenetelmä antiallergisena aineena aktiivisen bentsotiatsolijohdannaisen valmistamiseksi
IL90337A0 (en) * 1988-05-24 1989-12-15 Pfizer Aromatic and heterocyclic carboxamide derivatives as antineoplastic agents
CN1234358C (zh) * 2000-06-21 2006-01-04 弗·哈夫曼-拉罗切有限公司 苯并噻唑衍生物
WO2003045385A1 (en) * 2001-11-27 2003-06-05 F. Hoffmann-La Roche Ag Benzothiazole derivatives
US6727247B2 (en) * 2001-12-10 2004-04-27 Hoffman-La Roche Inc. Substituted benzothiazole amide derivatives
US6734179B2 (en) * 2001-12-12 2004-05-11 Hoffmann-La Roche Inc. Benzothiazoles
KR100699615B1 (ko) * 2003-01-13 2007-03-23 에프. 호프만-라 로슈 아게 벤족사졸 유도체 및 아데노신 수용체 리간드로서의 이들의용도

Also Published As

Publication number Publication date
AU2004251814A1 (en) 2005-01-06
JP4444290B2 (ja) 2010-03-31
DK1636223T3 (da) 2008-06-23
EP1636223B1 (en) 2008-03-19
CO5630031A2 (es) 2006-04-28
BRPI0410440A (pt) 2006-06-06
NZ543074A (en) 2009-01-31
PL1636223T3 (pl) 2008-07-31
SI1636223T1 (sl) 2008-06-30
AU2004251814B2 (en) 2009-07-23
CL2004001067A1 (es) 2005-04-15
KR20060013406A (ko) 2006-02-09
HK1092469A1 (zh) 2007-02-09
RU2005139527A (ru) 2006-07-27
KR100859886B1 (ko) 2008-09-23
ES2301991T3 (es) 2008-07-01
CA2524366A1 (en) 2005-01-06
ATE389652T1 (de) 2008-04-15
DE602004012555D1 (de) 2008-04-30
IL171686A (en) 2011-11-30
CN100528871C (zh) 2009-08-19
ZA200509294B (en) 2006-10-25
US20040235915A1 (en) 2004-11-25
TW200505882A (en) 2005-02-16
CN1791600A (zh) 2006-06-21
MXPA05012360A (es) 2006-02-02
EP1636223A1 (en) 2006-03-22
JP2006528220A (ja) 2006-12-14
HRP20080207T3 (en) 2008-06-30
RU2351597C2 (ru) 2009-04-10
PT1636223E (pt) 2008-05-06
AR044362A1 (es) 2005-09-07
US7371748B2 (en) 2008-05-13
WO2005000842A1 (en) 2005-01-06
CA2524366C (en) 2012-03-13
DE602004012555T2 (de) 2009-04-16

Similar Documents

Publication Publication Date Title
ES2584055T3 (es) Compuestos heterocíclicos de benzodioxol o benzodioxepina como inhibidores de la fosfodiesterasa
AR040806A1 (es) Derivados de piperidi-2-ona 1,6 disustituidos, composicion farmaceutica que la comprende y metodo de tratamiento
CY1109558T1 (el) Παραγωγα βενζο[d]αζεπινης για την θεραπεια νευρολογικων διαταραχων
DK0944617T3 (da) Krystaller af benzimidazolderivater og deres fremstilling
CO5700774A2 (es) Derivados de triazol como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa-1
PE20030062A1 (es) Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas
YU48390B (sh) Novi derivati 2-anilinopirimidina, postupak za njihovo dobijanje i sredstva za uništavanje štetočina, koja sadrže ove derivate
AR037731A1 (es) Uso de ureas de benzotiazoles
DE68908040D1 (de) 3-(4-piperidin)-5-(2-sulphonylaminoethyl)-indol-derivate.
NO20080871L (no) N-(Heteroaryl)-1-heteroarylalkyl-1 H-indol-2-karboksamidderivater, fremstilling og terapeutisk anvendelse derav
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
ATE431345T1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
BR112019024376A2 (pt) composto de fórmula geral (i), ou sais farmaceuticamente aceitáveis destes, composição farmacêutica e uso dos compostos ou sais farmaceuticamente aceitáveis destes
AU2005288080A1 (en) Carbostyril compound
JP2005538111A5 (no)
NO20055150L (no) Benzotiazolderivater som adenosin-reseptorligander
BR0010134A (pt) Uso de derivados de ácido 2,4-diamino-3-hidroxicarboxìlico como inibidores de proteassoma
NO177138C (no) Analogifremgangsmåte ved fremstilling av substituerte imidazolderivater
AR036735A1 (es) Derivados de 5-metoxi-8-aril-[1,2,4]triazolo[1,5-a]piridina
PT76123B (fr) Procede de preparation de nouveaux derives de benzadioxine
NO20052360L (no) Forbedrede formuleringer inneholdende substituerte imidazolderivater
NO20055176L (no) Benzotiazolderivater og anvendelse derav i behandling av sykdommer vedrorende adenosin A2A-resepor
ATE8996T1 (de) Benzo(4,5)pyrano(2,3-c)pyrrole, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
NO20054794L (no) 7 ([1, 4] dioksan-2-yl)-benzotiazolderivater som adenosinreseptorligander
MY140692A (en) Benzothiazole derivatives

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application